Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fidelity MSCI Health Care Index ETF (NY:FHLC)

69.62 -0.01 (-0.01%)
Official Closing Price Updated: 4:10 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fidelity MSCI Health Care Index ETF

FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report
Via Stocktwits
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study
Via Stocktwits
BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later
Via Stocktwits
Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations
A federal court blocked NIH's policy capping indirect cost rates on research grants, ruling it unlawful. The decision safeguards billions in funding and ongoing clinical trials. 
Via Benzinga
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
ETFs In Focus Post UnitedHealth's Mixed Q4 Results
UnitedHealth Group, the largest U.S. health insurer, reported mixed fourth-quarter 2024 results. Shares of the stock dropped nearly 6% on the day following the results. This put various ETFs in the... 
Via Talk Markets
Topics ETFs Stocks / Equities
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups
A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments. 
Via Benzinga
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
Worried About the Markets? Buy and Hold These 2 Cheap ETFs.
These funds have generated returns north of 60% over the past five years and make for relatively safe investments. 
Via The Motley Fool
Healthcare ETFs in Focus as Q2 Earnings Unfold
Let’s dig deeper into the earnings picture of the companies which will drive the performance of healthcare funds in the coming days. 
Via Talk Markets
Healthcare ETFs on Radar As Q1 Earnings Unfold
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.